Functional Antibodies and Innate Immune Responses to WRSS1, a Live Oral Shigella Sonnei Vaccine Candidate, in Bangladeshi Adults and Children
Overview
Authors
Affiliations
Background: We demonstrated in a randomized placebo-controlled trial that WRSS1, a live oral Shigella sonnei vaccine candidate, is safe in Bangladeshi adults and children, and elicits antigen-specific antibodies. Here, we describe functional antibody and innate immune responses to WRSS1.
Methods: Adults (18-39 years) and children (5-9 years) received 3 doses of 3 × 105 or 3 × 106 colony forming units (CFU) of WRSS1 or placebo, 4 weeks apart; children additionally received 3 × 104 CFU. Blood and stool were collected at baseline and 7 days after each dose. Functional antibodies were measured using serum bactericidal antibody (SBA) assay. Cytokine/chemokine concentrations were measured in lymphocyte cultures. Host defense peptides LL-37, HBD-1, and HD-5 were analyzed in plasma and stool.
Results: Children showed increased SBA titers over baseline after the third dose of 3 × 106 CFU (P = .048). Significant increases of Th-17 and proinflammatory cytokines (TNF-α, G-CSF, MIP-1β), and reduction of anti-inflammatory and Th2 cytokines (IL-10, IL-13, GM-CSF) were observed in children. Plasma HBD-1 and LL-37 decreased in children after vaccination but were increased/unchanged in adults.
Conclusions: Functional antibodies and Th1/Th17 cytokine responses in children may serve as important indicators of immunogenicity and protective potential of WRSS1. Clinical Trials Registration: NCT01813071.
Vaccines: The Continuing Unmet Challenge.
Lu T, Das S, Howlader D, Picking W, Picking W Int J Mol Sci. 2024; 25(8).
PMID: 38673913 PMC: 11050647. DOI: 10.3390/ijms25084329.
Conti V, Rossi O, Clarkson K, Mancini F, Nakakana U, Sarakinou E NPJ Vaccines. 2024; 9(1):56.
PMID: 38459072 PMC: 10923941. DOI: 10.1038/s41541-024-00822-2.
Kapulu M, Muthumbi E, Otieno E, Rossi O, Ferruzzi P, Necchi F Front Immunol. 2024; 15:1340425.
PMID: 38361949 PMC: 10867106. DOI: 10.3389/fimmu.2024.1340425.
Shrivastava S, Agnememel A, Ndungo E, Islam D, Liang Y, Frenck Jr R mSphere. 2023; 9(1):e0041923.
PMID: 38132716 PMC: 10826362. DOI: 10.1128/msphere.00419-23.
Refining Immunogenicity through Intradermal Delivery of Outer Membrane Vesicles against in Mice.
Pastor Y, Calvo A, Salvador-Erro J, Gamazo C Int J Mol Sci. 2023; 24(23).
PMID: 38069232 PMC: 10706920. DOI: 10.3390/ijms242316910.